The Bethesda System Revisited: Malignancy Risk Estimation and NIFTP Impact in a Large Cohort From Northern India
Diagnostic Cytopathology · 2025
DOI: 10.1002/dc.70074 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diagnostic Cytopathology, 2025. Verfasst von Shruti Singh und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Hind Institute of Medical Sciences, Lucknow, India. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Thyroid Nodule, Adenocarcinoma, Follicular. Die Arbeit nennt 30 Literaturangaben.
Abstract (Originalsprache)
Background
Thyroid nodules are common in clinical practice, and fine‐needle aspiration cytology (FNAC) remains the primary test for malignancy risk assessment. The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) standardizes interpretation and guides management. This study evaluated the distribution of Bethesda categories, risk of neoplasia (RON) and malignancy (ROM), and the impact of non‐invasive follicular thyroid neoplasm with papillary‐like nuclear features (NIFTP) on risk stratification.
Methods
A retrospective review of 2578 thyroid FNACs (2016–2024) was conducted at King George's Medical University, Lucknow. Cytological diagnoses were classified using TBSRTC (2017 and 2023). Histopathological correlation was available in 1043 cases (40.5%). RON and ROM were calculated for each category, with ROM assessed before and after excluding NIFTP. Smears were independently reviewed by two cytopathologists, and diagnostic metrics (sensitivity, specificity, accuracy) were derived using histopathology as reference; 95% confidence intervals were estimated by exact binomial methods.
Results
Most cases were Benign (73.2%), followed by Malignant (7.2%) and Follicular Neoplasm (6.1%). Malignancy was confirmed in 245 cases. ROM ranged from 3.7%–9.9% (Benign) to 58.6%–100% (Malignant), showing a progressive rise across categories. Reclassification of NIFTP notably reduced ROM for indeterminate categories (AUS: 43.2% → 31.8%; FN: 40.2% → 28.4%; SM: 52.4% → 42.9%).
Conclusion
TBSRTC reliably stratifies malignancy risk in thyroid nodules. Reclassification of NIFTP has a substantial impact on ROM in indeterminate categories, underscoring the need for precise cytologic‐histologic correlation and regional validation to optimize patient management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pathology, Hind Institute of Medical Sciences, Lucknow, India.
- Department of Pathology, King George's Medical University, Lucknow, India.
- Department of Endocrine Surgery, King George's Medical University, Lucknow, India.
ORCID-Profile: Shruti Singh, Chanchal Rana, Pooja Ramakant, Kul Ranjan Singh, Anand Mishra
Zitieren
APA
Singh, S., Rana, C., Ramakant, P., Singh, K. R., & Mishra, A. (2025). The Bethesda System Revisited: Malignancy Risk Estimation and NIFTP Impact in a Large Cohort From Northern India. Diagnostic Cytopathology. https://doi.org/10.1002/dc.70074
Vancouver
Singh S, Rana C, Ramakant P, Singh KR, Mishra A. The Bethesda System Revisited: Malignancy Risk Estimation and NIFTP Impact in a Large Cohort From Northern India. Diagnostic Cytopathology. 2025. doi:10.1002/dc.70074
BibTeX
@article{Singh2025,
author = {Singh, Shruti and Rana, Chanchal and Ramakant, Pooja and Singh, Kul Ranjan and Mishra, Anand},
title = {The Bethesda System Revisited: Malignancy Risk Estimation and NIFTP Impact in a Large Cohort From Northern India},
journal = {Diagnostic Cytopathology},
year = {2025},
doi = {10.1002/dc.70074}
}
EUVIMED